Ionis Pharmaceuticals cut its 2026 sales forecast for TRYNGOLZA from $100-110 million to about $50 million due to a slower-than-expected commercial launch. This significant downgrade raised concerns about whether the company had previously disclosed challenges in sales and commercialization. Following the announcement, Ionis shares dropped over 25% in intraday trading. The situation has prompted a securities investigation by Kehoe Law Firm for investors who suffered losses.
Ionis Pharmaceuticals (IONS) shares on Pluang have fallen sharply by 28.18% to USD 28.31 as of Nov 09, 2026 22:21 WIB, reflecting significant investor reaction to the company's revised sales outlook. The stock's market capitalization stands at $6.55 billion with a trading volume of 2,911,470 shares, indicating active trading. This drop aligns with the news of a major sales forecast cut and ongoing legal scrutiny.
